Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.40 |
| ▸ | OPRD1 | P41143 | 4/20 | 0.40 |
| ▸ | OPRK1 | P41145 | 4/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.31 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.31 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11028956 | 1.00 | ALDH1A1 (0.46) | ALDH1A1OPRM1OPRD1OPRK1MAPT | |
| SCHEMBL9945707 | 0.91 | ALDH1A1 (0.40) | ALDH1A1OPRM1OPRD1OPRK1MAPT | |
| SCHEMBL12039759 | 0.90 | ALDH1A1 (0.43) | ALDH1A1OPRM1OPRD1OPRK1MAPT | |
| Trolamine SCHEMBL11794009 | 0.89 | MAPT (0.43) | ALDH1A1OPRM1OPRD1OPRK1MAPT | |
| SCHEMBL13143549 | 0.87 | CYP1A2 (0.47) | ALDH1A1OPRM1OPRD1OPRK1MAPT | |
| SCHEMBL472095 | 0.85 | ALDH1A1 (0.43) | ALDH1A1OPRM1OPRD1OPRK1CYP1A2 | |
| SCHEMBL11815318 | 0.84 | ALDH1A1 (0.43) | ALDH1A1OPRM1OPRD1OPRK1TSHR | |
| SCHEMBL9945683 | 0.84 | ALDH1A1 (0.38) | ALDH1A1OPRM1OPRD1OPRK1MAPT | |
| SCHEMBL10935340 | 0.83 | CHRM2 (0.35) | ALDH1A1OPRM1OPRD1OPRK1 | |
| Fluoride SCHEMBL23302253 | 0.82 | ALDH1A1 (0.42) | ALDH1A1OPRM1OPRD1OPRK1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024098053-A1 | POLYMER-NUCLEIC ACID NANOPARTICLES FOR GENE EDITING | THE JOHNS HOPKINS UNIVERSITY (US) | 2024-05-10 | — | — | WO | disclosed |
| WO-2023212057-A1 | COMPOSITIONS OF KINETIC NANOPARTICLES CONTAINING NUCLEIC ACIDS, POLYCATIONS AND LIPIDS | THE JOHNS HOPKINS UNIVERSITY (US) | 2023-11-02 | — | — | WO | disclosed |
| US-20230293706-A1 | Multicomponent Delivery Systems for Polyanionic Cargo Compound Delivery | MEDICI THERAPEUTICS, INC. | 2023-09-21 | — | — | US | disclosed |
| US-11697804-B2 | Transcriptionally targeted and CpG-free plasmid for theranostic gene therapy | THE JOHNS HOPKINS UNIVERSITY (US) | 2023-07-11 | — | — | US | disclosed |
| WO-2023077150-A1 | POLYMERS AND NANOPARTICLES FOR INTRAMUSCULAR NUCLEIC ACID DELIVERY | THE JOHNS HOPKINS UNIVERSITY (US) | 2023-05-04 | — | — | WO | disclosed |
| US-20230002790-A1 | POLY(Beta-AMINO ESTER) NANOPARTICLES FOR THE NON-VIRAL DELIVERY OF PLASMID DNA FOR GENE EDITING AND RETINAL GENE THERAPY | THE JOHNS HOPKINS UNIVERSITY | 2023-01-05 | — | — | US | disclosed |
| US-20220040331-A1 | COMPOSITIONS AND METHODS FOR TRANSFECTING CELLS | AMRYT RESEARCH LIMITED (IE) | 2022-02-10 | — | — | US | disclosed |
| US-20210388196-A1 | GENE DELIVERY CARRIER | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2021-12-16 | — | — | US | disclosed |
| US-20210369867-A1 | LIPID NANOPARTICLE FORMULATIONS COMPRISING LIPIDATED CATIONIC PEPTIDE COMPOUNDS FOR NUCLEIC ACID DELIVERY | NUTCRACKER THERAPEUTICS, INC. (US) | 2021-12-02 | — | — | US | disclosed |
| WO-2021030218-A1 | LIPIDATED CATIONIC PEPTIDE-PEG COMPOSITIONS FOR NUCLEIC ACID DELIVERY | NUTCRACKER THERAPEUTICS, INC. (US) | 2021-02-18 | — | — | WO | disclosed |
| US-20120149630-A1 | END-MODIFIED POLY(BETA-AMINO ESTERS) AND USES THEREOF | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2012-06-14 | — | — | US | disclosed |
| US-20100228015-A1 | PRODRUG DERIVATIVES OF ACIDS USING ALCOHOLS WITH HOMOTOPIC HYDROXY GROUPS AND METHODS FOR THEIR PREPARATION AND USE | DELONG MITCHELL A | 2010-09-09 | — | — | US | disclosed |
| US-20100228015-A1 | PRODRUG DERIVATIVES OF ACIDS USING ALCOHOLS WITH HOMOTOPIC HYDROXY GROUPS AND METHODS FOR THEIR PREPARATION AND USE | DELONG MITCHELL A | 2010-09-09 | — | — | US | disclosed |
| US-7642245-B2 | Antibacterial compounds having a (pyrrole carboxamide)-(benzamide)-(imidazole carboxamide) motif | OSCIENT PHARMACEUTICALS CORPORATION (US) | 2010-01-05 | — | — | US | disclosed |
| US-20080242626-A1 | End-Modified Poly(beta-amino esters) and Uses Thereof | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2008-10-02 | — | — | US | disclosed |
| US-20080242626-A1 | End-Modified Poly(beta-amino esters) and Uses Thereof | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2008-10-02 | — | — | US | disclosed |
| US-20070254920-A1 | Prodrug derivatives of acids using alcohols with homotopic hydroxy groups and methods for their preparation and use | AERIE PHARMACEUTICALS, INC. (US) | 2007-11-01 | — | — | US | disclosed |
| US-20070254920-A1 | Prodrug derivatives of acids using alcohols with homotopic hydroxy groups and methods for their preparation and use | AERIE PHARMACEUTICALS, INC. (US) | 2007-11-01 | — | — | US | disclosed |
| US-20070142268-A1 | Antibacterial compounds having a (pyrrole carboxamide)-(benzamide)-(imidazole carboxamide) motif | OSCIENT PHARMACEUTICALS CORPORATION (US) | 2007-06-21 | — | — | US | disclosed |
| US-7160907-B2 | Pleuromutilin derivatives | SMITHKLINE BEECHAM P.L.C. (GB) | 2007-01-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149630-A1 | END-MODIFIED POLY(BETA-AMINO ESTERS) AND USES THEREOF | PARN, PARG, POLL | ALDH1A1 2664/4885OPRM1 1152/4885OPRD1 546/4885 |
| US-20230293706-A1 | Multicomponent Delivery Systems for Polyanionic Cargo Compound Delivery | MTREX, EXOSC5, KPNA6 | ALDH1A1 4262/4885OPRM1 3010/4885OPRD1 3748/4885 |
| US-20080242626-A1 | End-Modified Poly(beta-amino esters) and Uses Thereof | PARN, PARG, POLL | ALDH1A1 2664/4885OPRM1 1152/4885OPRD1 546/4885 |
| US-20070142268-A1 | Antibacterial compounds having a (pyrrole carboxamide)-(benzamide)-(imidazole carboxamide) motif | AADAC, MRPL21, HDAC6 | ALDH1A1 1422/4885OPRM1 603/4885OPRD1 1046/4885 |
| US-20070254920-A1 | Prodrug derivatives of acids using alcohols with homotopic hydroxy groups and methods for their preparation and use | HCAR1, HCAR2, PAICS | ALDH1A1 102/4885OPRM1 657/4885OPRD1 1028/4885 |
| US-20210388196-A1 | GENE DELIVERY CARRIER | PAICS, PBDC1, BCAT1 | ALDH1A1 2765/4885OPRM1 2200/4885OPRD1 1973/4885 |
| US-20210369867-A1 | LIPID NANOPARTICLE FORMULATIONS COMPRISING LIPIDATED CATIONIC PEPTIDE COMPOUNDS FOR NUCLEIC ACID DELIVERY | PHOSPHO1, PLIN3, CETP | ALDH1A1 4840/4885OPRM1 4277/4885OPRD1 4508/4885 |
| US-20100228015-A1 | PRODRUG DERIVATIVES OF ACIDS USING ALCOHOLS WITH HOMOTOPIC HYDROXY GROUPS AND METHODS FOR THEIR PREPARATION AND USE | HCAR1, HCAR2, PAICS | ALDH1A1 102/4885OPRM1 657/4885OPRD1 1028/4885 |
| US-11697804-B2 | Transcriptionally targeted and CpG-free plasmid for theranostic gene therapy | POLRMT, HDGF, PCNP | ALDH1A1 3433/4885OPRM1 2803/4885OPRD1 2337/4885 |
| US-20220040331-A1 | COMPOSITIONS AND METHODS FOR TRANSFECTING CELLS | TK1, XPA, RNASE1 | ALDH1A1 3345/4885OPRM1 4335/4885OPRD1 4262/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.